Logo image
Back
Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease
Journal article   Open access   Peer reviewed

Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease

Greta R Bauer, Seth L Welles, Robert R Colgrove and Jane Pitt
Journal of acquired immune deficiency syndromes (1999), v 34(3), pp 312-319
01 Nov 2003
DOI: https://doi.org/10.1097/00126334-200311010-00010
PMID: 14600578
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1097/00126334-200311010-00010View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open

Abstract

HIV Infections - prevention & control Pregnancy Complications, Infectious - virology Humans Drug Resistance, Viral RNA, Viral - blood CD4 Lymphocyte Count HIV-1 - genetics Pregnancy Point Mutation - genetics Phenotype HIV-1 - growth & development Pregnancy Complications, Infectious - drug therapy Inhibitory Concentration 50 Adult Female HIV Infections - drug therapy HIV Infections - transmission Zidovudine - therapeutic use Retrospective Studies Reverse Transcriptase Inhibitors - therapeutic use Infectious Disease Transmission, Vertical - prevention & control Infant, Newborn
The association of phenotypic zidovudine resistance with perinatal transmission was evaluated in 74 zidovudine-treated mothers enrolled in the Women and Infants Transmission Study through September 1994. Women in the sample had moderately advanced disease, with a median CD4+ cell count of 271/microL and a median plasma HIV-1 RNA level of 39,811 copies/mL. Factors independently associated with zidovudine resistance at delivery (50% inhibitory concentration [IC50], >/=0.1 microM) in multiple logistic regression included prepregnancy zidovudine use, high log plasma HIV-1 RNA level, and low CD4+ cell count. Of 74 mothers, 16 (22%) transmitted HIV-1 to their infants. After adjustment for duration of membrane rupture and CD8+ cell count, zidovudine resistance (IC50 range, 0.01-2.2 microM) was associated with an increased odds of transmission (ORadj, 1.25 per 0.1 microM; 95% confidence interval, 1.01-1.54), suggesting a decreased effect of prenatal zidovudine on preventing transmission in mothers infected with zidovudine-resistant virus. However, when the analysis was limited only to those mothers infected with virus containing zidovudine resistance mutations, no association between phenotypic resistance and transmission remained, indicating that phenotype may not provide significant additional information in predicting transmission where resistance genotype is known.

Metrics

5 Record Views
6 citations in Web of Science
6 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Immunology
Infectious Diseases
Logo image